Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme

Evidence from randomized controlled trials (RCTs) has shown that second‐generation basal insulin (BI) analogues, insulin glargine 300 U/mL (Gla‐300) and insulin degludec (IDeg), provide similar glycaemic control, with a lower risk of hypoglycaemia compared with the first‐generation BI analogue insul...

Descripción completa

Detalles Bibliográficos
Autores principales: Blonde, Lawrence, Bailey, Timothy, Sullivan, Sean D., Freemantle, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2021
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362061/
https://www.ncbi.nlm.nih.gov/pubmed/33881797
http://dx.doi.org/10.1111/dom.14405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362061/
https://www.ncbi.nlm.nih.gov/pubmed/33881797
http://dx.doi.org/10.1111/dom.14405

Ejemplares similares